Skip to content

Induced Pluripotent Stem Cells and 3D Bioprinting Strategies for Cardiac Regeneration After Myocardial Infarction

2026 · American Journal of Student Research · pp. 867-875 · 0 citations

TL;DR

This study evaluates the role of iPSCs and different biofabrication methods, such as bioprinting, used to create ventricular constructs and cardiac patches that support injured regions of the heart post-MI.

Abstract

Cardiovascular disease is the leading cause of death worldwide, often resulting in a myocardial infarction (MI), which can lead to irreversible cell death and heart failure (HF). While advances in bioengineering and regenerative medicine offer promising solutions for patients, traditional heart transplantations are limited due to a shortage of organ donors. To address this issue, differentiating induced pluripotent stem cells (iPSCs) into cardiomyocytes via signaling pathways can provide a patientspecific source of functional cardiomyocytes, and as a long-term goal it may be capable of replacing damaged myocardial tissue. This study evaluates the role of iPSCs and different biofabrication methods, such as bioprinting, used to create ventricular constructs and cardiac patches that support injured regions of the heart post-MI. However, for patients with HF, bioprinting a whole-heart construct is being explored as a future objective and is necessary to restore cardiac function when cardiac patches or ventricular constructs are not sufficient. Despite the progress made in the field, few studies have addressed the need to improve bioprinting vascular networks, adopt appropriate bioinks, and reduce costs for iPSC differentiation and bioprinting technologies. If successful, this work can eventually mitigate symptoms post-MI or contribute to addressing HF solutions, offering patients a new quality of life.

View source

Similar papers

Review Open access Sep 2026

Human iPSC models of myocardial infarction: From injury to repair and therapeutic discovery.

Myocardial infarction (MI) remains a leading cause of death worldwide, and therapies that limit injury, promote repair, and restore cardiac function remain limited. Human induced pluripotent stem cells (hiPSCs) provide a renewable source of patient-specific cardiac cells and have enabled the development of increasingly...

Benjamin B. Johnson, C. Mummery, Richard P. Davis · 0 citations
Review Open access Aug 2026

Cardiac stem cells as a source of myocardial regeneration

A review of the phenotypic and functional characteristics of different cardiac stem cell populations, their localization in the heart, age-related dynamics, changes in pathological conditions, as well as mechanisms of their pro-regenerative effects, and potential clinical applications examines the phenotypic and functi...

O. Payushina, Valeria Pykhanova, D. Tsomartova et al. · 0 citations
Review Open access Aug 2026

Stem Cell-Derived Cardiac and Conduction System Cells for Heart Regeneration and Repair: Current Progress and Future Directions.

This review evaluates recent developments in hiPSC technology, beginning with the generation of patient-specific models of inherited arrhythmias and cardiomyopathies, and examines progress in directing hiPSCs into specialized lineages, including cardiomyocytes, pacemaker cells, and Purkinje fibers.

Berra Koskulu, Tabish Ali, Ilkin Tetik-Altintop et al. · 0 citations
Review Open access Sep 2026

Human cardiovascular organoids: Biomedical applications and ethical challenges

A comprehensive synthesis of current cardiovascular organoid research is presented, emerging biomedical applications are highlighted, and a critical perspective on the ethical frameworks essential for advancing the field responsibly is provided.

Koushik Sen, Suravi Majumder, Dragana Stanišić et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.